5 completed, 4 unknown. 3 Phase 3, 2 Not applicable, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 2, Completed 1 |
| Not applicable | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Ranibizumab: new trials by email Literature Review of Ranibizumab trials Research Report on Ranibizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous Hemorrhage Ranibizumab - Diabetic Vitreous Hemorrhage, Intravitreal Injections | Phase 4 | Completed | Benha University | 30 | 2025-04-01 | 2026-07-08 |
| A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy Ranibizumab Injection, PPV - Diabetic Retinopathy, Postoperative Recurrent Vitreous Hemorrhage | Phase 1 | Unknown | Tianjin Medical University Eye Hospital | 120 | 2022-04-10 | 2022-08-12 |
| Effectiveness of Biosimilar Ranibizumab in the Management of Diabetic Macular Edema Ranibizumab biosimilar - Anti-VEGF Treatment, Ranibizumab | Completed | Benha University | 60 | 2022-01-01 | 2026-06-23 | |
| Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy Intravitreal injection of ranibizumab - Subfoveal Choroidal Thickness, Intravitreal | Not applicable | Completed | Egyptian Biomedical Research Network | 50 | 2021-02-01 | 2023-12-15 |
| Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity Ranibizumab (0.25 mg/0.025 mL) - Retina Disease, Retinopathy of Prematurity | Phase 3 | Completed | Zagazig University | 30 | 2020-11-20 | 2023-01-30 |
| Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion Ranibizumab, laser photocoagulation - Retinal Vein Occlusion, Treatment | Phase 4 | Unknown | Sun Yat-sen University | 100 | 2019-10-01 | 2019-08-20 |
| Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR) Ranibizumab, No drug - Diabetic Retinopathy, Ranibizumab | Phase 3 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 118 | 2018-04-01 | 2018-03-02 |
| Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO Ranibizumab combined macular laser, Ranibizumab - Branch Retinal Vein Occlusion, Ranibizumab | Not applicable | Completed | Beijing Hospital | 80 | 2017-02-14 | 2022-12-28 |
| Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Intravitreal ranibizumab - Glaucoma, Neovascular, Ranibizumab | Phase 3 | Unknown | LEANDRO CABRAL ZACHARIAS | 28 | 2016-10-01 | 2016-09-27 |
Diabetic Retinopathy (3) · Retinal Vein Occlusion (2) · Glaucoma, Neovascular (1) · Retinopathy of Prematurity (1)
Eye Diseases (7) · Retinal Diseases (6) · Cardiovascular Diseases (5) · Vascular Diseases (5) · Diabetes Complications (3) · Diabetes Mellitus (3) · Diabetic Angiopathies (3) · Endocrine System Diseases (3) · Embolism and Thrombosis (2) · Thrombosis (2) · Venous Thrombosis (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Glaucoma (1) · Infant, Newborn, Diseases (1) · Infant, Premature, Diseases (1)
Ranibizumab (7)
Benha University (2) · Beijing Hospital (1) · Egyptian Biomedical Research Network (1) · LEANDRO CABRAL ZACHARIAS (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Sun Yat-sen University (1) · Tianjin Medical University Eye Hospital (1) · Zagazig University (1)
China (4) · Egypt (4)
Chenjin Jin, Ph.D (1) · Ekram R Abd-Allah, Master (1) · Sherif Abbas Dabour, MD, FRCS (1) · Xiao-bing Yu, M.D (1) · Xun Xu (1)